Investor Presentation Q1 2023

72 Investor presentation First three months of 2023 Rare disease sales decreased by 16%, driven by driven by temporary reduction in manufacturing output DKK billion NovoSevenⓇ and NorditropinⓇ account for ~70% of Rare disease sales DKK billion Global Rare disease franchise 25 25 1% 4% 1% -16% 1% 4% 1% |-16% 20 20 20 15 10 5 0 2020 2021 2022 Q1 2023 NovoSevenⓇ NorditropinⓇ Other haemophilia products¹ Other Rare disease Growth at CER Source: Quarterly company announcement Note: Company reported sales; CER: Constant exchange rates; 1Other haemophilia products primarily consists of Vagifem® and ActivelleⓇ 8 15 7 7 10 12 12 13 5 2020 23 Novo NordiskⓇ 2021 2022 Q1 2023 IO NAO Growth at CER

View entire presentation